Charles River Laboratories
$ 232.51
-0.90%
31 Jul - close price
- Market Cap 11,301,112,000 USD
- Current Price $ 232.51
- High / Low $ 237.06 / 230.06
- Stock P/E N/A
- Book Value 61.05
- EPS -3.72
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE -0.06 %
- 52 Week High 242.73
- 52 Week Low 144.26
About
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Analyst Target Price
$228.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-18 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-19 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-14 | 2023-11-08 | 2023-08-09 |
| Reported EPS | 2.06 | 2.39 | 2.43 | 3.12 | 2.34 | 2.66 | 2.59 | 2.8 | 2.27 | 2.46 | 2.72 | 2.69 |
| Estimated EPS | 1.95 | 2.33 | 2.32 | 2.55 | 2.07 | 2.53 | 2.42 | 2.39 | 2.06 | 2.4 | 2.37 | 2.64 |
| Surprise | 0.11 | 0.06 | 0.11 | 0.57 | 0.27 | 0.13 | 0.17 | 0.41 | 0.21 | 0.06 | 0.35 | 0.05 |
| Surprise Percentage | 5.641% | 2.5751% | 4.7414% | 22.3529% | 13.0435% | 5.1383% | 7.0248% | 17.1548% | 10.1942% | 2.5% | 14.7679% | 1.8939% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 2.72 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRL
2026-07-30 20:48:02
Align Technology announced several corporate initiatives, including the appointment of three independent directors to its board and an increased share repurchase commitment, following discussions with activist investor Elliott Investment Management. These changes aim to strengthen commercial execution, enhance organizational effectiveness, and optimize resources. The company plans to repurchase between $400 million and $500 million of its common stock during 2026.
2026-07-30 17:07:25
Charles River Laboratories International, Inc. (CRL) is set to announce its second-quarter 2026 earnings on August 5th, with analysts forecasting a revenue decline of 5.9% and an EPS decrease of 12.8%. The company’s Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments are expected to show revenue declines due to various market pressures and divestitures, while the Manufacturing Solutions segment also faces a projected decrease. Despite these challenges, Charles River holds a Zacks Rank #2, and its Earnings ESP suggests a higher chance of beating estimates.
2026-07-30 10:57:00
Labcorp (LH) reported a 5.8% increase in second-quarter 2026 revenue to $3.73 billion, with diluted EPS rising to $3.64. The company raised its full-year revenue and adjusted EPS guidance and announced a $1.0 billion increase in its share repurchase authorization. Insider trading data shows significantly more sales than purchases, while institutional investors show mixed activity, and congressional members made purchases.
2026-07-30 05:54:39
This article provides a valuation analysis for Charles River Laboratories International Inc (CRL), noting its current valuation score and ranking within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio, comparing it to recent highs and lows, but states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
2026-07-30 05:07:29
Shares of Charles River Laboratories International Inc. (CRL) experienced a significant rise of 7.2% on Wednesday, outperforming its competitors. This strong performance indicates a positive market reaction to the company's recent activities or broader sector trends.
2026-07-29 17:16:00
Charles River Laboratories International Inc. (CRL) stock dropped 2.34% on Wednesday, closing at $234.80. This underperformance occurred on a generally poor trading day where both the S&P 500 and Dow Jones Industrial Average also saw significant declines. The company's shares finished 3.27% below its 52-week high.
